Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAB004 Monotherapy and Combination with Toripalimab in Advanced Solid Malignancies
NCT04137900Phase 1Recruiting
- Sponsor
- Top Alliance Biosciences
- Start
- Oct 2019
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tifcemalimab in solid tumor (advanced stage), lymphoma, melanoma and 3 more (9 arms), sponsored by Top Alliance Biosciences. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 2 years. Started Oct 2019; status: recruiting.
02
Drugs
tifcemalimab
03
Conditions
solid tumor (advanced stage)lymphomamelanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04137900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137900.